Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.47 |
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | JAK1 | P23458 | 3/20 | 0.41 |
| ▸ | TYK2 | P29597 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 4/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12953823 | 0.93 | GSK3B (0.49) | GSK3BJAK2JAK1TYK2JAK3 | |
| SCHEMBL12953762 | 0.85 | GSK3B (0.51) | GSK3BJAK2JAK1TYK2JAK3 | |
| SCHEMBL12954179 | 0.85 | GSK3B (0.67) | GSK3BCDK2CCNE1 | |
| SCHEMBL12953266 | 0.84 | GSK3B (0.51) | GSK3BJAK2JAK1TYK2JAK3 | |
| SCHEMBL12953558 | 0.84 | GSK3B (0.50) | GSK3BJAK2JAK1TYK2JAK3 | |
| SCHEMBL12953011 | 0.82 | GSK3B (0.63) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL13998622 | 0.79 | GSK3B (0.48) | GSK3BJAK2JAK1TYK2JAK3 | |
| SCHEMBL14412770 | 0.78 | GSK3B (0.67) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL12952905 | 0.78 | GSK3B (0.65) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL12953255 | 0.78 | CHEK1 (0.48) | GSK3BJAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586576-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | GSK3B 749/4885JAK2 246/4885JAK1 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.